Skip to content

Resultados da pesquisa

No Results

    Visualizados recentemente

      Listening...

      Sorry, I don't understand. Please try again

      1. Portugal /
      2. About us
      JJ_Photo_Father checking daughters temperature_GettyImages_1245148140_1Star.jpg
      About us
      At Johnson & Johnson Innovative Medicine, we’re creating a future where disease is a thing of the past.
      At Johnson & Johnson Innovative Medicine (formerly known as Janssen, The Pharmaceutical Companies of Johnson & Johnson), we innovate with purpose to lead where medicine is going. Inspired by patients and the legacy of industry pioneer Dr. Paul Janssen, we continue with the vision of developing science-based innovations to change and save lives.
      Today, we pursue new pathways, collaborate closely with doctors, and analyze data to deliver safe, reliable, and effective products that will transform the future of health. Our diverse and innovative product portfolio spans multiple focus areas —Oncology, Immunology, Neuroscience, Cardiopulmonary and Specialty Ophthalmology. We apply rigorous science and compassion to confidently address the most complex diseases of our time and take bold actions to deliver the support patients need.
      Johnson & Johnson Innovative Medicine is leading where medicine is going.
      Who is Johnson & Johnson Innovative Medicine?

      We are here to transform the future of health with you. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives.

      Who is Johnson & Johnson Innovative Medicine?
      Guided by the values in Our Credo, we apply high ethical standards in all areas of our business.
      Our responsibilities
      We are committed to the people we serve. We understand the needs of patients and healthcare professionals, and their experiences help inform the development of transformational medicines.
      • We are committed to grants and giving, and the principles of diversity, equity and inclusion in our workplace and beyond.
      • Guided by our access and pricing principles, we continue to work to expand access to our medicines to help patients get the treatments they need.
      • With our resources and expertise, we test and champion sustainable access models to advance health for all in an increasingly complex world.
      Our collaborations
      Our approach to collaboration helps drive our success. Healthcare providers, patient groups, governments, regulators and payers help us to better understand patient needs, so we can create new tools and programs to improve how patients access and experience our innovations.
      Images (1).png
      Images (2).png
      Images (3).png
      Images (1).png
      Our leadership
      Our leadership team is made up of experienced and passionate individuals who are here to transform the future of health with you. Inspired by patients, we take health personally because health is personal.
      Executive Vice President, Worldwide Chairman, Innovative Medicine, Johnson & Johnson
      63ad5febda1f479dc482c88265425f90.jpeg
      Leadership team
      At Johnson & Johnson Innovative Medicine, we aspire to improve individual patient health outcomes, enable health system productivity, improve population health and maintain sustainable innovation for patients today and tomorrow.
      As part of Johnson & Johnson, we work to understand and address the serious health problems of today and unlock the potential medicines of tomorrow.
      Our awards
      Our work, dedication and expertise have been recognized around the world.
      • #2 in Pharmaceutical Category of FORTUNE World’s Most Admired Companies List
        Johnson & Johnson has been named to the top spot for 10 consecutive years.
      • #2 in Access to Medicine Index
        Johnson & Johnson has been ranked in the top three for more than a decade. In this independent benchmark, the world’s largest pharmaceutical companies are graded on efforts to distribute medicines to low- and middle-income countries.